Camp4 CFO Kelly Gold buys $39,600 in company stock

Kelly Gold, Chief Financial Officer of Camp4 Therapeutics Corp (NASDAQ:CAMP), purchased 10,000 shares of the company’s common stock on August 31, 2026. The transaction totaled $39,600.

The shares were acquired in multiple open market transactions at prices ranging from $3.88 to $4.00 per share, with a weighted average price of $3.96 per share. The purchase comes as the stock has declined roughly 8% over the past week, according to InvestingPro data, though shares remain up an impressive 170% over the past year.

The shares are held in a brokerage account in the name of David Gold, Ms. Gold’s spouse. Ms. Gold has stated that she does not exercise investment control over this account and disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein. InvestingPro analysis suggests the stock is currently undervalued, with 10 additional ProTips available to subscribers seeking deeper insights into Camp4 Therapeutics’ investment potential.

In other recent news, CAMP4 Therapeutics has been the focus of analyst attention with notable upgrades and initiations. JPMorgan upgraded CAMP4 Therapeutics from Neutral to Overweight, raising its price target to $9.00 from $5.00, citing potential in the company’s CMP-002. Additionally, Chardan initiated coverage on CAMP4 Therapeutics with a buy rating and set a price target of $6.50. These developments reflect a positive outlook from analysts regarding CAMP4’s future prospects. In a separate announcement, X4 Pharmaceuticals appointed Kelly Gold to its board of directors. Gold, who is the current CFO at CAMP4 Therapeutics, will also serve as a member of X4’s audit committee. These recent developments highlight strategic movements within both companies.